Angiogenesis, the development of new blood vessels from existing vasculature, is crucial for the development and metastasis of solid tumors. Here, we show for the first time that a 24-amino acid peptide derived from the amino terminus of the alpha chain of human fibrinogen (termed 'alphastatin') has potent anti-angiogenic properties, inhibiting both the migration and tubule formation of human dermal microvascular endothelial cells in response to VEGF or bFGF in vitro. Moreover, alphastatin markedly inhibits the growth of tumors in a syngeneic murine model. Tumors from mice receiving daily injections of alphastatin for 12 days exhibited large areas of intravascular disruption and thrombosis, with substantial cellular necrosis.
INTRODUCTION
Angiogenesis, the growth of new capillaries from an existing host vascular bed, involves the migration, proliferation and differentiation of endothelial cells and is crucial for the growth and metastasis of tumors 1 . Hemostatic mechanisms control blood flow by regulating platelet adherence and fibrin deposition, and various hemostatic proteins have also been implicated recently in angiogenesis [2] [3] [4] .
Fibrinogen accumulation, and subsequent clotting to form a fibrin meshwork in the stroma, has long been recognised as a feature of solid tumors, and is thought to result from prominent vascular permeability in these tissues [5] [6] . This has led to speculation that fibrin may be important in initiating and/or maintaining tumour angiogenesis. However, subsequent experiments using fibrinogen-deficient mice, have shown that while fibrinogen/fibrin deficiency inhibits the formation of metastasis in mice, it fails to inhibit primary tumour angiogenesis or growth 7 .
We have previously demonstrated that a 50kDa fragment containing the central domain of human fibrinogen (fibrinogen E-fragment; FgnE), formed when plasmin cleaves the carboxy termini of the paired -, -and -chains of fibrinogen, is a potent anti-angiogenic factor. It inhibits VEGF-induced migration and tubule formation by human dermal microvascular endothelial cells (HuDMECs) in vitro 8 and tumor growth in a syngeneic murine model in vivo by selectively disrupting tumor endothelium and causing widespread intravascular thrombosis 9 .
Fibrinogen can also be cleaved by thrombin which removes the amino termini of both the -and -chains, termed fibrinopeptide A and B respectively, to yield fibrin monomers. These in turn are cleaved by plasmin to produce the fragment closely related to FgnE, fibrin E-fragment (FnE). This has been shown to be proangiogenic, stimulating the migration and tubule formation of HuDMECs in vitro 10 
,
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From and vessel formation in the chick chorioallantoic membrane (CAM) assay 11 . As plasmin cleaves the amino terminus of the -chain between aa42 and 43, in both Efragments, the anti-angiogenic FgnE only differs from FnE in that the former contains 16 amino acids at the end of each amino terminus of the -chains, and is called fibrinopeptide A (FpA) (Fig. 1a) . These are not present in FnE. This led us to speculate that the anti-angiogenic properties of FgnE may be mediated by FpA.
However, when a linear form of FpA was tested it was found to be inactive in vitro 10 .
The crystal structure of fibrinogen has been described 12 , and nuclear magnetic resonance studies have suggested the presence of a -bend conformation at the NH 2 -terminus of each -chain 13 . This may be stabilised by a salt bridge between Asp 7 and
Arg 19 , and the -bend would place Phe 9 in close proximity to the thrombin cleavage site (the Arg 16 -Gly 17 bond) 13, 14 . We proposed, therefore, that each FpA is held in abend conformation at the end of the -chains of FgnE, and that this conformation may be essential for the anti-angiogenic activity of FgnE (Fig. 1b) . We synthesised the first 24 amino acids of the alpha chain of fibrinogen (which included the salt bridge between Asp 7 and Arg 19 ) and called the resultant peptide, 'alphastatin' (see Fig. 1 ).
The present studies demonstrate that alphastatin inhibits the ability of vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) to stimulate the migration and differentiation of human dermal microvascular endothelial cell (HuDMEC) in vitro. Furthermore, daily intraperitoneal injections of alphastatin in a syngeneic tumour model also selectively disrupt tumor endothelium in vivo, causing widespread intravascular thrombosis and retarding tumour growth.
MATERIALS AND METHODS
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From Cells and cell culture. Adult HuDMECs were obtained commercially (TCS Cell Works, Buckinghamshire, UK) and cultured in microvascular endothelial cell growth medium. This medium contains heparin (10ng/ml), hydrocortisone, human epidermal growth factor (10ng/ml), human fibroblast growth factor (10ng/ml) and dibutyryl cyclic AMP. The medium was supplemented with 5% heat-inactivated fetal calf serum, 50µg/ml gentamicin, and 50ng/ml amphotericin B (TCS Cell Works). An SV40-transformed murine endothelial cell line, SVEC4-10, was obtained from ATCC. The murine colonic adenocarcinoma CT26 cell line is a N-nitrosos-Nmethylurethane induced Balb/c tumor obtained from Professor Ian Hart, ICRF, London, UK. These murine cell lines were maintained by in vitro passage in Dulbecco's Minimal Eagle's Medium (DMEM), 10% fetal calf serum, 1% penicillin and streptomycin. Cells were grown at 37 o C in a 100% humidified incubator with a gas phase of 5% CO 2 and routinely screened for Mycoplasma .
Proteins and Peptides.
Recombinant human VEGF 165 and bFGF were purchased from R&D systems (Abingdon, UK). Alphastatin was synthesised by Dr A Moir (Molecular Biology and Technology, University of Sheffield, Sheffield, UK) using standard peptide synthesis techniques, and purified to >93% using HPLC.
Migration assay. The migration assay, adapted from (15) involved the use of a 48 well microchemotaxis chamber (Neuro Probe Inc, Cabin John, MD) with 8µm pore size polycarbonate membranes (Neuro Probe, Inc, Cabin John, MD) coated with 100µg/ml collagen type IV. 10ng/ml VEGF or bFGF alone or with various concentrations of alphastatin (10nM, 100nM, 1000nM) were dissolved in DMEM + 1%FCS and placed in the lower wells. The membrane was then positioned and 50µl The absorbance was then read at 540nm using a Dynex ELISA plate reader.
Tubule formation assay. 24 well plates were coated with 30µl/well of growth factor reduced (GF-reduced) Matrigel (Becton Dickinson Labware, Bedford, MA).
Endothelial cells on this matrix migrated and formed tubules within 6 hours of plating 17 . Cells (HuDMECs and SVEC4-10) were seeded at 4x10 4 cells/ml and incubated for 6 hours in 50µl DMEM + 1%FCS alone (control), or medium + 10, 100, 1000nM alphastatin, and with or without 10ng/ml bFGF or VEGF. Wells were then fixed and stained with haematoxylin and eosin, visualized (at x40 magnification), and tubule formation assessed in three randomly selected fields of view per well using the image analysis package, Scion Image, as described by us 8 . 20 . Tumor necrosis was assessed using a Chalkley grid method as described previously 21 .
Vascular density assessment. Zinc-fixed sections were exposed to a rat monoclonal anti-murine CD31 (1:100; Pharminogen, CA, USA) specific for endothelial cells, for 60 minutes at room temperature and immunoreactivity detected using the ABC rat elite kit (Vector Laboratories, UK) and diaminobenzidine. Maximal vascular density was quantified using the Chalkley grid method 22 .
Statistical Analysis. All data shown are means + S.E.M. and representative data from one of three replicate experiments are shown. Statistical analysis was performed using a Mann Whitney U-test for non-parametric data. Data was considered statistically significant at p<0.05.
RESULTS

Effects of alphastatin on HuDMEC in vitro.
Initial experiments were performed to determine whether alphastatin affected the three main stages in the angiogenesis pathway. and found to have no detectable cytotoxic effect at these doses (data not shown).
When HuDMECs were pre-exposed to alphastatin (1000nM) for two hours, and washed prior to addition to the GFR-Matrigel assay, the tubule formation of these HuDMECs was inhibited to the same extent as cells that were exposed to alphastatin during the course of the assay (Fig. 2d) .
Comparison between the effects of alphastatin and FgnE on HuDMECs in vitro
As alphastatin is derived from FgnE, we compared equimolar concentrations of the two proteins on the migration and tubule formation of HuDMECs. Although both proteins inhibit migration and tubule formation of HuDMEC in vitro, FgnE was significantly more effective at inhibiting than alphastatin at the highest two doses (100 & 1000nM) in both the presence and absence of VEGF (10ng/ml) (See Figure 3) .
Secondary structure is necessary for alphastatin activity
As alphastatin consists of FpA (aa1-16) attached to a further 8 amino acids, we synthesised the short peptide, aa17-24. When this and FpA were tested in the CFRMatrigel experiment, neither were seen to inhibit tubule formation (data not shown).
This was in direct contrast to alphastatin, which at equimolar concentrations caused a significant inhibition of tubule formation.
Effects of alphastatin on murine cells in vitro.
Although fibrinogen is a highly conserved protein cross-species, there are minor differences between rodents and humans [23] [24] . Alphastatin is derived from the human fibrinogen -chain sequence, therefore it was necessary to establish that human alphastatin inhibited murine endothelial cell function prior to the evaluation of activity in vivo. Alphastatin was found to inhibit tubule formation by the murine microvascular endothelial cell line, SVEC4-10, both in the absence and presence of the growth factors bFGF and VEGF (data not shown). The effects of alphastatin on the growth and cytotoxicity of the murine tumor cell line investigated in this paper, CT26, were tested in the MTT proliferation assay and propidium iodide staining of cells on the FACs. Alphastatin did not alter CT26 cell proliferation over a 96 hour exposure period nor was it cytotoxic for these cells over a 24 exposure period, at doses of up to 10µM (data not shown).
Effects of alphastatin on tumor growth.
As FgnE has previously been shown by us to inhibit the growth of CT26 tumors grown in Balb/C mice (a syngeneic tumor model) 9 , the same model was used to determine the effects of Alphastatin in vivo. CT26 tumors implanted subcutaneously reached 100-350mm 3 in volume between days 14-18 following implantation. At this time animals were allocated into either treatment (alphastatin 0.025mg/kg/day; n=7) or control (PBS; n=6) groups. Animals were then injected intraperitoneally every day for 12 days according to the appropriate regimen (PBS or alphastatin in PBS).
Tumors in the control group continued to grow steadily over the treatment period, reaching a final tumor volume of 2642+363mm 3 . However, animals injected with alphastatin exhibited a significantly (p<0.05) reduced growth rate between days 5-12, reaching a final tumor volume of only 1212+174mm 3 (Fig. 4a) . Similar results were obtained in two further cohorts of such tumor-bearing mice. Alphastatin administration appeared to be well tolerated in vivo, with no significant effect on body weight or the general well-being of the animals (as determined by the absence of lethargy, intermittent hunching, tremors or disturbed breathing patterns).
Effects of alphastatin on tumor histology.
Histological 
and the central necrotic core of alphastatin treated than control tumors. In the outer viable rim of alphastatin treated tumors, although the vessel lumen remained patent and contained red blood cells, fibrin deposition was evident around many vessels. Alphastatin was found to have no such effects on the endothelium in the normal tissues examined (lungs, liver and kidneys; Fig. 4c ).
DISCUSSION
We have previously shown that a proteolytic cleavage product of fibrinogen, FgnE, inhibits endothelial cell migration and tubule formation in vitro 8 and growth of CT26
tumors in vivo 9 . The present study shows that a small peptide derived from the amino-terminus of the -chain of human fibrinogen mimics these effects of FgnE.
The delay in CT26 tumor growth appeared to be largely due to endothelial disruption and increased microvascular thrombosis; an effect restricted to activated tumor endothelium over the treatment period studied.
We originally proposed that the fact that alphastatin was held in a -bend conformation within the FgnE molecule was essential for its inhibitory effects on activated endothelial cells. This was supported by the fact that neither the FpA portion of alphastatin (aa1-16) nor aa17-24 were found to mimic the inhibitory effects of alphastatin in vitro 10 .
Comparing the effects of FgnE and alphastatin, it can be seen that FgnE at an equivalent dose is more effective at inhibiting both migration and tubule formation of endothelial cells. This may be due to further conformational constraints placed on the amino-terminal of the -chain when it is bound to the parent FgnE protein (that are missing in alphastatin assays. Therefore FgnE may have dual active sites, one being the amino-terminus of the -chain, and another that has yet to be determined.
The fact that alphastatin inhibits the migration and tubule formation of HuDMECs in response to both VEGF or bFGF, suggests that these effects most likely operate at a post-receptor locus common to the VEGF and bFGF signalling pathways in these cells. Reports by Sahni and co-workers [26] [27] indicate that fibrinogen is capable of binding to both VEGF and bFGF, but neither appear to bind to the alphastatin region of fibrinogen [27] [28] , so it is unlikely that alphastatin inhibits the action of these growth factors by such an indirect mechanism. Furthermore, exposure of HuDMEC to alphastatin for two hours, prior to addition of the cells to the GFR-Matrigel assay in vitro (which was then run in the absence of alphastatin), was sufficient to A general activation of hemostatic pathways is unlikely as no signs of thrombosis or fibrin deposition was observed in blood vessels in the lungs, liver or kidneys of alphastatin-treated mice. Indeed most of the vessels in these healthy tissues were packed with erythrocytes, indicating that vessels were not occluded. This important observation indicates that alphastatin binds to activated rather than quiescent endothelial cells and confirms that the receptor(s) for alphastatin may be expressed only on activated endothelium in tumor vessels. This also supports a possible therapeutic role for alphastatin as an agent to specifically target activated endothelium in areas of angiogenesis, rather than endothelial cells in the quiescent vasculature.
It will be noted that the vascular counts were higher in alphastatin-treated animals in the inner, less viable rim of tumor cells abutting the areas of necrosis (when this was present) compared to the same region in control tumors. This was not due to an increase in tumor angiogenesis but a consequence of the dilation of, and thrombosis within, vessels in these tumor areas, causing an increased number of intersections between each vessel and the Chalkley grid. 
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Although alphastatin treatment resulted in marked signs of vessel coagulation and concomitant necrosis in CT26 tumors, a thin, outer viable rim of these tumors (in which both vessels and tumour cells were largely unaffected) was usually also present. One explanation for this unaffected outer viable rim may be that, as subcutaneous CT26 tumors grow, they co-opt pre-existing vessels from the surrounding tissue rather than generate new vessels by angiogenesis. This would mean that vessels in the outer viable rim would be unlikely to be actively proliferating -and thus may not express the receptor(s) for alphastatin.
As it remained a possibility that alphastatin could mediate its effects in vivo by causing an inhibition in tumor cell growth or induction of apoptosis of CT26 cells, we tested the effects of alphastatin on CT26 cells in vitro. Lengthy exposures to alphastatin in vitro had no effect on CT26 viability or proliferation, suggesting that alphastatin does not target tumor cells directly in this murine tumor model. Taken together, these in vitro and in vivo observations suggest that alphastatin targets blood vessels in tumors, causing endothelial cell damage and triggering a hemostatic response (i.e. fibrin deposition and thrombosis). This is likely to have gradually occluded affected vessels, causing inadequate perfusion of surrounding areas and increased necrosis, which in turn reduced tumor growth in vivo.
Neutrophils are known to play a role within tumor angiogenesis 29 and it has been demonstrated that the adhesion molecule CD11c/CD18 on neutrophils, interacts with amino acids 17-19 (Gly-Pro-Arg) on the -chain of fibrinogen 30 . This sequence of amino acids is also contained within the alphastatin molecule, therefore it is possible that side effects may be induced in vivo, including enhanced susceptibility to bacterial infection. However, it is unclear whether such binding occurs when the alphastatin sequence is no longer part of the whole fibrinogen molecule.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Unfortunately, it was not possible to obtain murine alphastatin due to the lack of published data on the murine fibrinogen -chain sequence. Therefore, the possibility exists that the effects on the tumor vasculature and growth observed in the current studies were due, at least in part, to the potential immunogenic effects of human alphastatin in mice. However, this is an unlikely explanation for the observed effects as there was no visible microscopic evidence of a peritoneal cellular reaction to alphastatin injections, and histological analysis of lungs, liver and kidneys from alphastatin-treated animals showed no cellular or structural abnormalities. Following prolonged application of human alphastatin in mice, a loss of antivascular efficacy may occur due to a humoral reaction to the injected protein, which could mean that the therapeutic efficacy of long-term administration of human alphastatin might be greater in humans than in the mice used here. The effects of alphastatin shown here were obtained using a relatively low dose of alphastatin and a short period of administration (12 days). However, a similar inhibition of tumor growth was also seen when the dose of alphastatin was increased ten-fold to 0.25mg/kg/day and the injection period extended by a further five days (data not shown).
In conclusion, the data presented demonstrate for the first time that a small peptide derived from the amino-terminus of the -chain of fibrinogen (alphastatin) inhibits both endothelial cell migration and tubule formation in vitro and the growth Tubule formation by HuDMEC on GF-reduced Matrigel in response to medium alone (control) or medium containing 10 ng/ml VEGF or bFGF. D) Tubule formation by HuDMECs exposed to either alphastatin (1000nM) for 2 hours prior to the assay and then washed and added to the assay in the absence of alphastatin (but in the presence or absence of bFGF (10ng/ml) or VEGF (10ng/ml)) or HuDMECs exposed to alphastatin (1000nM) during the assay alone (in the presence or absence of bFGF (10ng/ml) or VEGF (10ng/ml)). All data shown are means + S.E.M. *p<0.03 compared to respective 'no alphastatin' groups. 
